RFM.STU Sensorion SA

Healthcare Biotechnology Stuttgart Exchange
0.9120 EUR
Close of Oct 13, 2026
5.30 41.50
Market cap
EUR 470M
P/E
-
P/B
1.09x
ROE
-66.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is RFM.STU undervalued?

Graham number

The Graham number of Sensorion SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Sensorion SA fundamental analysis

No fundamental analysis for Sensorion SA yet.

Sensorion SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Sensorion SA

Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. Its pipeline includes various products in the development stage for restoring, treating, and preventing inner ear related disorders. The company's product portfolio includes SENS-401 SSNHL, which has completed Phase 2 clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2 clinical trial for the treatment of Cispla…

Full company profile